Benchmark Payments. 10 3.10 Royalties............................................................. 10 3.11
Benchmark Payments. With respect to [ * ], Merck shall pay to Tularik:
(a) [ * ];
(b) [ * ];
(c) [ * ];
(d) [ * ].
Benchmark Payments. (The information marked by *** has been omitted by a request for confidential treatment. The omitted portions will be separately filed with the Commission.)
Benchmark Payments. (a) Taisho shall pay Tularik within [ * ] after the occurrence of the following events: [*] up to an aggregate of $3 million.
(b) Taisho shall pay Tularik within [ * ] after the occurrence of the following events: [*] up to an aggregate of $3 million.
Benchmark Payments. CUSTOMER shall be required to make the following payments to DYAX upon achievement of the following benchmarks, *************: Benchmark Payment --------- ------- First ************* ************* by CUSTOMER or any of its affiliates or sublicensees for a Licensed Product First ************* ************* by CUSTOMER or any of its affiliates or sublicensees for a Licensed Product First ************* ************* by CUSTOMER or any of its affiliates or sublicensees for a Licensed Product First ************* Licensed ************* Product in the United States or any country in Europe by Customer or any of its affiliates or sublicensees
Benchmark Payments. [*****] ------------------ ***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SEC. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. [*****]
Benchmark Payments. (a) Taisho shall pay Tularik within [ * ] after the occurrence of the following events: [ * ].
(b) Taisho shall pay Tularik within [ * ] after the occurrence of the following events: [ * ].
Benchmark Payments. In addition to Licensee’s funding obligations set forth above, Licensee shall make the following benchmark payments (the “Benchmark Payments”) to Licensor as set forth below:
(a) Licensee agrees that within seven (7) business days of the Effective Date of this Agreement, Licensee shall make a non-creditable, non-refundable one-time payment of $1,200,000 to Licensor.
(b) Licensee agrees that within 30 days of the earlier of (i) the achievement of the stage of preparation of an INTERACT for a Product, which shall be mutually determined in good faith by the Authorized Officer and the Executive Director of SRI, or (ii) or Pre-IND meeting with the FDA for a Product, Licensee shall make a one-time, non-refundable, non-creditable payment of $1,500,000 to Licensor.
(c) Licensee agrees that within thirty (30) days of the receipt of approval by the FDA of the first IND for a Product, Licensee shall make a one-time, non-creditable, non-refundable payment of $2,500,000 to Licensor.
(d) Licensee agrees that within thirty (30) days of the receipt of FDA Approval for a Product, Licensee shall make a one-time, non-creditable, non-refundable payment of $10,000,000 to Licensor within 30 days.
Benchmark Payments. Signature of this Amendment and transfer of rights to any applicable patents and know-how concerning the countries and territories listed under Far East in Attachment under B ** million US$ Transfer of rights to any applicable patents and know-how and approval of Licensed Products with respect to the first of ****** or ****** or ****** ** million US$ Transfer of rights to any applicable patents and know-how and approval of Licensed Products with respect to the second of ****** or ****** or ****** ** million US$ Transfer of rights to any applicable patents and know-how and approval of Licensed Products with respect to the third of ****** or ****** or ****** ** million US$ -------------- ** million US$ Payments for each benchmark shall be due only in case such benchmark is completed.
Benchmark Payments. 5.2.1 YAMANOUCHI shall make the determination whether or not each of Delivered Samples has a binding affinity not less than 25% of the corresponding original Murine Anti-gpllb/llla Antibody or fragments thereof ("Binding Affinity Requirement") within sixty (60) days after receipt of such Delivered Samples. YAMANOUCHI and PDL agree that binding affinity will be measured by the method of competitive binding set forth in Queen, et al., Proceedings of the National Academy of Sciences, USA, 86, 1030 (1989). YAMANOUCHI agrees to provide PDL with samples of Murine Anti-gpllb/llla Antibody, F(ab')2 and Fab fragments thereof in order for PDL to perform the competitive binding assay. In addition, PDL agrees to perform Scatchard plot analyses of Delivered Samples. If such Delivered Samples meet the Binding Affinity Requirement, YAMANOUGHI shall pay PDL [ ] ("First Benchmark Payment") within thirty (30) days after such determination. If YAMANOUCHI has not determined the binding affinity within sixty (60) days after receipt of last Delivered Sample, then First Benchmark Payment is due ninety (90) days after receipt of last Delivered Sample.
5.2.2 YAMANOUCHI and PDL shall promptly commence inhibition of platelet aggregation and other in vitro assays as described in Exhibit A to determine the biological activity of Delivered Samples. Within one (1) month of receipt by YAMANOUCHI of the last of Delivered Samples, YAMANOUCHI shall inform PDL in writing if the platelet aggregation inhibition activity of each CONFIDENTIAL TREATMENT REQUESTED Delivered Sample does or does not meet YAMANOUCHI's criteria for further development.
5.2.3 If YAMANOUCHI informs PDL that one or more of Delivered Samples meets YAMANOUCHI's criteria for further development, PDL shall commence production of sample quantities sufficient for further testing. YAMANOUCHI shall pay PDL [ ] ("Second Benchmark Payment") within four (4) months of receipt by YAMANOUCHI of: [ ] mg of humanized anti-gpllb/llla intact antibody; [ ] mg of humanized F(ab')2 fragment thereof; and [ ] mg of humanized Fab fragment thereof. Concurrent with such payment, YAMANOUCHI shall inform PDL in writing as to which cell line YAMANOUCHI wishes PDL to deliver pursuant to Paragraph 5.2.4.
5.2.4 YAMANOUCHI shall pay PDL [ ] ("Third Benchmark Payment") upon receipt of the producer cell line requested by YAMANOUCHI pursuant to Paragraph 5.2.3, said producer cell line having an expression level, as measured under standard tissue culture co...
